Sickle Cell Patients Show High Interest in Gene Therapy Despite Awareness Gaps, EHA Data Reveal
Data presented at EHA show that sickle cell disease patients have high interest in gene therapy, with 71% eager to learn more, despite limited awareness and concerns about safety and cost. Early clinical data from approved CRISPR-based therapies demonstrate significant reductions in vaso-occlusive crises and hospital admissions.
A survey of sickle cell disease patients reveals strong interest in gene therapies, even as many lack awareness of these treatments, according to data presented at the European Hematology Association (EHA) congress. The findings, drawn from a cohort of 94 individuals, show that 71% of patients expressed a strong interest in learning more about gene therapy, but 49% reported limited or no awareness of gene editing, and 56% felt inadequately informed about the risks and benefits. Safety was the primary concern for 33% of respondents, while 53% identified cost and funding as a major barrier to access. The most desired outcomes from treatment were reduction or prevention of vaso-occlusive crises (24%), complete cure (18%), and improved quality of life (14%). Additionally, 54% rated access to cutting-edge therapy as very important.
Gene therapy has moved decisively from scientific ambition to clinical reality, redefining what is possible for patients with severe genetic conditions like sickle cell disease, where curative intent is now a regulated, deployable therapeutic pathway. Early clinical data from approved CRISPR-based therapies demonstrate dramatic reductions in vaso-occlusive crises and hospital admissions in treated patients, reinforcing the transformative potential of these platforms. However, sustaining that impact across diverse populations and health systems will depend on the ability to capture real-world outcomes in a structured, transparent, and longitudinal way. Post-treatment monitoring that includes pain patterns, sleep quality, activity levels, and patient-reported outcomes can provide a dynamic view of recovery, moving beyond binary success metrics to understand durability and quality of life improvement. Such real-world intelligence also creates strategic upside for pharmaceutical and biotechnology companies, strengthening outcomes-based reimbursement models, refining patient selection, and building trust through transparent data ecosystems. Gene therapy’s inflection point is not simply about editing DNA, but about redesigning care around curative intent and ensuring that scientific breakthroughs are embedded within systems capable of sustaining, measuring, and scaling their impact.